Key facts
- It has raised $8.8M; the latest was Later Stage VC ($1.9M) in Apr 2025.
- Notable investors include United States Department of War, United States Department of Agriculture, BioDimensions, Demos Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for GreenLab (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for GreenLab (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GreenLab (Biotechnology)
Operator of a biotechnology company intended to focus on delivering bio-based technologies providing a new generation of single-activity enzymes. The company's platform offers proteins that can meet rising demand in markets while also driving transformational growth through applications that scale production, enabling clients to get access to plant proteins, end-to-end sustainability, and scalability.
- Sector
- Healthcare
- HQ
- Jonesboro, AR, United States
- Founded
- 2006
- Employees
- 5
- Website
- greenlab.com/
- Ownership
- Privately Held (backing)
GreenLab (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GreenLab (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GreenLab (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.